SCYNEXIS, Inc. — Form 8-K Summary
Event date: September 25, 2026. The company announced the contract by press release on September 28, 2026. This 8-K reports a material agreement; it does not provide quarterly or annual financial statements.
Business context and agreement
SCYNEXIS entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA) to support development of SCY-247, its second-generation fungerp antifungal candidate. The initial base period begins in September 2026 and supports advancement of oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis.
Financial and funding details
- BARDA may provide up to $214 million in total non-dilutive funding. This is potential funding, not a guaranteed award of the full amount.
- The initial base period provides approximately $18.5 million. Further funding depends on BARDA exercising up to six options; all options together could extend the contract for up to ten years.
- The contract is a cost-share arrangement. BARDA supports eligible SCY-247 costs, including direct and general and administrative expenses. The filing does not specify the company’s full cost-share amount.
- SCYNEXIS expects to fund its share of near-term SCY-247 costs within its existing operating plan. Management says its previously communicated SCY-770 development plans and projected cash runway into 2029 remain unchanged.
- The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures for the reporting period.
Potential program scope and changes
If BARDA exercises all options, the contract could fund SCY-247 development through NDA submissions to the FDA for treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients. The agreement is a potential source of program funding; it does not assure trial success, NDA submission, or FDA approval. The company says the agreement does not change its stated SCY-770 plans or cash-runway projection.
Risks, contingencies, and unusual items
Future funding beyond the base period is contingent on BARDA exercising options. The company identifies development, clinical-trial timing, financing needs, economic and competitive conditions, inflation, interest rates, and market disruptions as risks that could cause actual results to differ from forward-looking statements. The full contract, with confidential terms redacted, was planned for filing as an exhibit to the company’s Form 10-Q for the quarter ending September 30, 2026.
Key facts for investors to verify
- Whether BARDA exercises any options and how much funding is ultimately available and received.
- The contract’s detailed cost-sharing obligations and eligible-cost terms when the redacted agreement is filed.
- SCY-247 trial initiation, progress, and results, and whether development advances toward the contemplated NDA submissions.
- Whether the company’s SCY-770 plans and projected cash runway into 2029 remain achievable as costs and funding evolve.